Guest, this browser only · 425 unread · 0 saved · pick a name · updated Nov 20, 6:10 pm
Background. The combination of docetaxel, trastuzumab, and pertuzumab (THP) is an established first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. The efficacy and safety of anbenitamab, a HER2-targeted bispecific antibody, plus albumin-bound docetaxel (HB1801) in this context are unknown.
Methods. In this phase 3, multicenter, open-label, randomized trial conducted in China, we randomly assigned patients with HER2-positive advanced breast cancer in a 1:1 ratio to receive either anbenitamab plus HB1801 or THP. The primary end point was progression-free survival, as assessed by blinded independent central review. Objective response was a secondary end point.
Results. A total of 885 patients were enrolled (445 were assigned to receive anbenitamab plus HB1801 and 440 to receive THP). At this prespecified interim analysis (with 401 events [disease progression or death] and a median follow-up of 21.0 months), the estimated 24-month progression-free survival was significantly higher with anbenitamab plus HB1801 than with THP (58.5% vs. 34.4%; hazard ratio for progression or death, 0.46; 95% confidence interval, 0.37 to 0.56; P<0.001). The percentage of patients with an objective response was 87.6% in the anbenitamab group and 73.4% in the THP group. Adverse events of grade 3 or higher occurred in 204 of 444 patients (45.9%) in the anbenitamab group and in 151 of 439 patients (34.4%) in the THP group. Neutropenia was the most common adverse event of grade 3 or higher in both groups (13.1% in the anbenitamab group and 8.4% in the THP group). Adverse events leading to death occurred in 2 patients in each group.
Conclusions. Anbenitamab plus HB1801 led to significantly higher progression-free survival than THP among patients with HER2-positive advanced breast cancer. (Funded by Shanghai JMT-Bio Technology and others; HEALER ClinicalTrials.gov number, NCT05838066.).
A note or tag saves the article on its own.
Background. The safety of omitting up-front treatment with aspirin during primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) remains unclear.
Methods. We conducted a multicenter, open-label, randomized trial in Japan involving patients with STEMI who were undergoing primary PCI. Patients were randomly assigned in a 1:1 ratio before PCI to receive low-dose prasugrel monotherapy or dual antiplatelet therapy (DAPT) with aspirin and low-dose prasugrel for 12 months. The primary outcome was a composite of death from any cause, stroke, or myocardial infarction at 12 months, which was assessed for noninferiority with a prespecified noninferiority margin of 1.50 for the 95% confidence interval of the hazard ratio. The major secondary outcome was major bleeding (defined as a bleeding event of Bleeding Academic Research Consortium [BARC] type 3 [nonfatal major bleeding] or 5 [fatal bleeding]) at 12 months, which was assessed for superiority if noninferiority was established for the primary outcome.
Results. A total of 2216 patients were included in the full analysis population; 1109 were assigned to receive monotherapy and 1107 to receive DAPT. At 12 months, death from any cause, stroke, or myocardial infarction had occurred in 124 patients (Kaplan-Meier estimate, 11.0%) in the monotherapy group and in 94 patients (Kaplan-Meier estimate, 8.5%) in the DAPT group (hazard ratio, 1.34; 95% confidence interval [CI], 1.02 to 1.75; Pā=ā0.40 for noninferiority). Major bleeding had occurred in 61 patients (Kaplan-Meier estimate, 5.6%) in the monotherapy group and in 92 patients (Kaplan-Meier estimate, 8.4%) in the DAPT group (hazard ratio, 0.66; 95% CI, 0.47 to 0.91). The percentages of patients with definite or probable stent thrombosis and serious adverse events appeared to be similar in the two groups.
Conclusions. Among patients with STEMI who were undergoing primary PCI, low-dose prasugrel monotherapy initiated before PCI was not noninferior to DAPT for 12 months with respect to a composite of death from any cause, stroke, or myocardial infarction at 12 months. (Funded by Boston Scientific Japan; PREMIUM ClinicalTrials.gov number, NCT05709626.).
A note or tag saves the article on its own.
Background. Endovascular thrombectomy is an established treatment for acute ischemic stroke. Whether the benefit extends to patients with salvageable brain tissue in the infarct who present more than 24 hours after symptom onset or the time when they were last known to be well is uncertain.
Methods. We conducted an open-label, randomized trial with blinded outcome assessment at comprehensive stroke centers in China. Patients with acute ischemic stroke from large-vessel occlusion of the anterior circulation and imaging-identified salvageable brain tissue at 24 to 72 hours were assigned to receive endovascular therapy plus standard medical care (intervention group) or standard medical care alone (control group). The primary outcome was functional status, defined by the score on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability and a score of 6 indicating death) at 90 days, with results assessed as the distribution of scores in each group. Secondary outcomes included disability, neurologic impairment, and safety.
Results. A total of 336 patients were included in the intention-to-treat population, with 168 assigned to each group. The median time from symptom onset or from the point when the patient was last known to be well to randomization was 38.5 hours. Endovascular therapy resulted in a more favorable distribution of modified Rankin scale scores at 90 days than standard medical care alone (common odds ratio for a better functional outcome, 1.74; 95% confidence interval, 1.19 to 2.55). Symptomatic intracranial hemorrhage occurred in 4.8% of the patients in the intervention group and in no patients in the control group, and the 90-day case fatality rate was 6.0% and 1.8%, respectively.
Conclusions. Among patients who presented 24 to 72 hours after an acute ischemic stroke from large-vessel occlusion of the anterior circulation and had imaging-identified salvageable tissue, endovascular therapy resulted in better functional outcomes than standard care but led to a higher risk of intracranial hemorrhage and death. (Funded by the National Health Commission Capacity Building and Continuing Education Center and others; LATE-MT ClinicalTrials.gov number, NCT05326932.).
A note or tag saves the article on its own.
Background. Whether endovascular therapy benefits patients with mild acute ischemic stroke from large-vessel occlusion involving the anterior circulation is uncertain.
Methods. We conducted a multicenter, open-label, randomized trial in China involving patients with acute ischemic stroke of mild clinical severity (defined by a score of <6 on the National Institutes of Health Stroke Scale) that had resulted from large-vessel occlusion involving the anterior circulation. Patients also had neuroimaging features of a small infarct core and a large perfusion-mismatch volume, representing substantial at-risk tissue, within 24 hours after symptom onset or after they were last known to be well. The patients were randomly assigned to undergo endovascular therapy and receive medical management or to receive medical management alone. The primary outcome was an excellent functional outcome (defined by a modified Rankin scale score of 0 [no symptoms] or 1 [no clinically significant disability]) at 90 days.
Results. A total of 304 patients underwent randomization, of whom 300 were included in the modified intention-to-treat population: 144 in the endovascular-therapy group and 156 in the medical-management group. At 90 days, a modified Rankin scale score of 0 or 1 was reported in 69.4% of the patients in the endovascular-therapy group and in 50.0% of those in the medical-management group (odds ratio, 2.32; 95% confidence interval, 1.41 to 3.81; P<0.001). Symptomatic intracranial hemorrhage within 48 hours occurred in 3 patients in each group. Serious procedure-related complications occurred in 19 patients (13.2%) in the endovascular-therapy group. Among all the participants, one death occurred (in the endovascular-therapy group).
Conclusions. In this trial from China involving patients with mild acute ischemic stroke caused by large-vessel occlusion and substantial at-risk tissue on perfusion imaging, endovascular therapy performed within 24 hours after symptom onset plus medical management resulted in better 90-day functional outcomes than medical management alone, without an increase in the risk of symptomatic intracranial hemorrhage but with a high incidence of serious procedural complications. (Funded by Fujian Medical University Union Hospital and others; MILD-MT ClinicalTrials.gov number, NCT06179017.).
A note or tag saves the article on its own.